Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada.
Department of Medicine and Division of Geriatric Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
J Am Geriatr Soc. 2019 Jun;67(6):1182-1188. doi: 10.1111/jgs.15774. Epub 2019 Jan 30.
Polypharmacy, defined as the use of five or more medications, has been repeatedly linked to fall incidence, and recently it was cross-sectionally associated with gait disturbances. Our objectives were to evaluate cross-sectional and longitudinal associations between polypharmacy and gait performance in a well-established clinic-based cohort study. We also assessed whether gait impairments could mediate associations between number of medications and fall incidence.
Prospective cohort of community-dwelling older adults, with 5 years of follow-up.
Geriatric clinics in an academic hospital in London, ON, Canada.
Community-dwelling older adults aged 65 and older (n = 249; 76.6 ± 8.6 y; 63% women).
Number of medications, quantitative spatiotemporal gait parameters, and fall incidence during follow-up.
The number of medications was cross-sectionally associated with poor gait performance (slow gait, speed p < .001; higher variability, p < .001; and higher stride, p < .001; step, p = .013, and double support times, p < .001). Prospectively, the number of medications was associated with overall gait decline (odds ratio = 1.23; 95% confidence interval [CI] = 1.13-1.33; p < .001), faster gait decline (hazard ratio = 4.62; 95%CI = 1.82-11.73; p < .001), and higher falls incidence (p = .006). These associations remained true after adjusting for age, sex, and accounting for "confounding by indication bias" by using a comorbidity propensity score adjustment. Each additional medication taken, significantly increased gait decline risk by 12% to 16% and fall incidence risk by 5% to 7%. Mediation analyses revealed that gait impairments in stride length, step length, and step width mediated the strength of the association between medications and fall incidence.
Polypharmacy was cross-sectionally associated with poor gait performance and longitudinally associated with gait decline and fall incidence. Despite our use of propensity matching, confounding by indication could have influenced the results. Quantitative spatial gait parameters performance mediated the strength of the association between medications and falls, suggesting a role of gait disturbances in the medication-related falls pathway.
定义为使用五种或更多种药物的多药治疗与跌倒发生率反复相关,最近还与步态障碍呈横断面相关。我们的目标是在一项成熟的基于诊所的队列研究中评估多药治疗与步态表现之间的横断面和纵向关联。我们还评估了步态障碍是否可以介导药物数量与跌倒发生率之间的关联。
社区居住的老年成年人的前瞻性队列研究,随访 5 年。
加拿大安大略省伦敦学术医院的老年科诊所。
年龄在 65 岁及以上的社区居住的老年成年人(n = 249;76.6 ± 8.6 岁;63%为女性)。
随访期间的药物数量、定量时空步态参数和跌倒发生率。
药物数量与较差的步态表现呈横断面相关(慢步态,速度 p <.001;更高的变异性,p <.001;更高的步长,p <.001;步长,p =.013,双支撑时间,p <.001)。前瞻性地,药物数量与整体步态下降相关(比值比= 1.23;95%置信区间[CI] = 1.13-1.33;p <.001),步态下降更快(危险比= 4.62;95%CI = 1.82-11.73;p <.001),跌倒发生率更高(p =.006)。这些关联在调整年龄、性别以及通过使用共病倾向评分调整来考虑“指示性偏倚混杂”后仍然成立。每增加一种药物,步态下降风险增加 12%至 16%,跌倒发生率风险增加 5%至 7%。中介分析表明,步长、步长和步宽的步态障碍中介了药物与跌倒发生率之间关联的强度。
多药治疗与步态表现呈横断面相关,与步态下降和跌倒发生率呈纵向相关。尽管我们使用了倾向匹配,但指示性偏倚可能会影响结果。定量空间步态参数表现介导了药物与跌倒之间关联的强度,表明步态障碍在与药物相关的跌倒途径中起作用。